Bio

Bio


Dr. Crystal Chang is a Hospital Dentist and Clinical Instructor in Dental Oncology and Oral Medicine & Maxillofacial Surgery. She focuses on maintaining oral health through the management of infection, trauma and secondary comorbidities to the dentition and its supporting structures. She performs medically necessary dental extractions in the context of cardiac disease, orthopedic surgery, cancer therapy and organ transplants.

Clinical Focus:
Hospital Dentistry
Dental Surgery
Dental Oncology

Clinical Focus


  • Dentistry
  • Dental Oncology
  • Orofacial Trauma

Academic Appointments


Professional Education


  • Residency, Veterans Affairs, Palo Alto Healthcare System, Hospital Dentistry (2016)
  • DDS, University of California, San Francisco, Dentistry (2015)
  • BA, Harvard University, Molecular and Cellular Biology

Publications

All Publications


  • Oropharyngeal carcinoma arising after methotrexate and etanercept therapy for rheumatoid arthritis ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY Chainani-Wu, N., Chang, C., Gross, A. J., Yom, S. S., Silverman, S. 2014; 117 (3): E261-E263

    Abstract

    Etanercept is an anti-tumor necrosis factor α receptor agent used to treat inflammatory conditions. Previous reports described rapid development of skin squamous cell carcinoma (SCC) after etanercept use. This report describes a novel case of oropharyngeal SCC associated with the use of etanercept. A 45-year-old man with rheumatoid arthritis developed oropharyngeal pain within 2 months after the start of etanercept therapy and was diagnosed with tonsillar carcinoma. This patient had other exposures that increase the risk of oropharyngeal cancer, such as tobacco and alcohol use. However, owing to the timing of onset of his initial symptoms, etanercept should be considered as a possible factor in the etiology or progression of his tumor, especially in the context of reported skin SCC after etanercept therapy in patients at risk for SCC. Clinicians should be alert to signs of malignancy in patients on etanercept, particularly those at high risk for skin or head and neck cancers.

    View details for DOI 10.1016/j.oooo.2013.11.499

    View details for Web of Science ID 000331062700006

    View details for PubMedID 24528797